- Latest Cancer News
- Anal Cancer
- Bladder Cancer
- Bone Cancer
- Brain Cancer
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Complementary Alternative Medicine
- Esophageal Cancer
- Gastric Cancer
- Gene Therapy
- Head and Neck Cancer
- HIV Related Cancers
- Hodgkin's Lymphoma
- Leukemia
- Liver Cancer
- Lung Cancer
- Lung Cancer - Non-Small Cell
- Lung Cancer - Small Cell
- Lymphoma
- Melanoma
- Mesothelioma
- Miscellaneous
- Multiple Myeloma
- Myelodysplastic Syndrome
- Neuroblastoma
- Non-Hodgkin's Lymphoma
- Osteosarcoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Rectal Cancer
- Renal Cancer
- Retinoblastoma
- Sarcoma
- Skin Cancer
- Stem Cell Transplant
- Supportive Care
- Testicular Cancer
- Throat Cancer
- Thyroid Cancer
- Uterine Cancer
- Vaginal Cancer
The U.S. Food and Drug Administration (FDA) has performed a systematic review of the long-term safety and efficacy of bisphosphonates and has recommended caution and updated labeling, but stopped short of imposing a regulatory restriction on the duration... Continue Reading
Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading
Women are 30 percent more likely to survive melanoma than men, according to the results of a study published in the Journal of Clinical Oncology.[1] Melanoma is a deadly type of skin cancer that arises from melanocytes, which are cells located in the... Continue Reading
Patients with newly diagnosed multiple myeloma who receive Revlimid® (lenalidomide) may be at an increased risk of developing new cancers, according to a safety announcement released by the U.S. Food and Drug Administration (FDA). Revlimid is an oral... Continue Reading
Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published in the Journal of Clinical Oncology. Lung cancer... Continue Reading
The final analysis of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) indicated that vitamin E increased the risk of developing prostate cancer in otherwise healthy men by 17% when compared to placebo. The results of the study were published... Continue Reading
Low-dose radioiodine is as effective as high-dose in the treatment of thyroid cancer, according to the results of two separate studies published in the New England Journal of Medicine. The results mean that radiation doses could be cut to one-third of... Continue Reading
The U.S. Food and Drug Administration (FDA) has approved a silicone gel-filled breast implant manufactured by Sientra Inc for breast augmentation in women at least 22 years old and breast reconstruction in women of any age. As a condition of approval,... Continue Reading